Repetitive counterelectrophoresis (RCE), which has been described (Hayano and Tanaka, 1977), was used to assay the contents of antibodies to streptococcal esterases (STE) in sera from patients with scarlet fever. The levels of antibodies to STE were expressed semiquantitatively by reading the intensity of the colored spot developed by RCE with a densitometer. The present study deals with the determination of anti-STE in sera drawn at intervals from 54 patients diagnosed as suffering from scarlet fever. The STE used in this study were prepared from the streptococcal strains as follows. STE-Al was prepared from SS379 (group A, type 40), STE-AII from strain 69882 (group A, type 49), STE-B from strain H36B (group B, lb), and STE-C from strain Austin (group C). Of the 54 cases studied, 32 (59.3%) showed anti-STE-Al, 24 (44.4%) showed anti-STE-AII, 5 (9.3%) showed anti-STE-B, and 23 (42.6%) showed anti-STE-C. Comparison of the titer of anti-streptolysin 0 (ASLO) with the type of specific reaction of anti-STE-AI and -All, determined in the same specimen, showed a marked correlation. Of 20 cases giving ASLO titers of 12 or less, 18 showed no sign of anti-STE-AI and -All and two showed signs of anti-STE-AL. Of 34 cases giving ASLO titers of more than 12, 33 showed signs of anti-STE-AI and/or -All, 22 showed signs of anti-STE-AI and -All, 7 showed signs of anti-STE-Al, and 4 showed signs of anti-STE-AI. Of all the cases, 26 showed coincident rises in titers of ASLO and levels of anti-STE-AI and/or -All during the course of the disease. One case showed the presence of only anti-STE-B. All of the 23 cases that showed the presence of anti-
In the preceding paper (2), we published a method, repetitive counter electrophoresis (RCE), for demonstrating the specific antibody to streptococcal esterase (STE), and we confirmed the immunological specificity of STE produced by some strains of group A, B, and C streptococci. Although many methods for detecting the antibodies to the various streptococcal antigens have been published it seems worthwhile to try to use this method for practical purposes, because there have been no reports concerning the practical application of this method based on the determination of anti-STE except for the report of Stock and Lynn (4), who have demonstrated the distribution of some anti-STE in sera of normal people of various ages.
This study deals with the distribution of some anti-STE in sera drawn from the patients diagnosed as suffering from scarlet fever, and it follows the change in levels of anti-STE-Al and -AII during the course of the disease compared with the change in titers of anti-streptolysin 0 (ASLO) determined in the same specimens.
MATERIALS AND METHODS STE enzymes. All preparations were as described in the preceding paper (2) . Sera. A total of 164 specimens were drawn from 54 patients aged from 4 to 9 years (mean, 6.4 years). They were diagnosed as suffering from scarlet fever and were admitted to the Toshima Hospital (Tokyo, Japan) during the period from September 1974 to May 1975. Two to four blood specimens were drawn from each patient at intervals of about 2 weeks. Before testing, the sera were incubated in a water bath at 560C for 30 min.
Assay of anti-STE and ASLO. Anti-STE was determined by RCE as described in the preceding paper (2) , and the level of anti-STE was determined by reading the intensity of color of the specific reaction line or spot with a densitometer (Fujiox, Fujidenki Co., Japan), using a filter of 650 nm and an aperture of 0.1 by 3 mm. The level of anti-STE was given by the number indicated by the densitometer, which expressed the integration of optical density. This number expresses the relative intensity of the colored spot, i.e., the numbers developed by serum no. 
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Isolation of organisms. Throat specimens were taken at intervals from the patients, and isolation of the organisms was done at Toshima Hospital. Classification of group A streptococci was done by M-antigen typing, and the isolated strains were of types 3, 4, 6, and 12.
RESULTS
To prove that the figure obtained by densitometry was a semiquantitative expression of the level of anti-STE, the following experiment was designed. Serial twofold dilutions were made with sera no. 13-2 and 16-3 in phosphatebuffered saline. The contents of each dilution were subjected to RCE, using STE-AI in the case of serum no. 13-2 and STE-II in the case of no. 16-3. (Fig. 1 ) Table 1 shows the relationship between the dilution of serum and the number obtained by densitometry. The level of anti-STE is expressed by the number obtained by densitometry. Table 2 shows the distribution of anti-STE in sera, giving the total number of cases showing the presence of antibody to each STE. Table 3 shows the levels of anti-STE and other data of selected cases. Table 4 illustrates the correlation between ASLO titers and the levels of anti-STE-AI and -AII, which were determined in the same specimens. Of 20 cases showing ASLO titers of 12 or less, 18 gave no sign of anti-STE-AI and -AII and two showed signs of anti-STE-AI. Of 34 cases showing ASLO titers of more than 12, 33 showed signs of anti-STE-AI and/or All, 22 showed signs of anti-STE-AI and -AII, 9 showed signs of only anti-STE-AI, 3 showed signs of only anti-STE-AII, and 1 gave no sign of anti-STE-Al or -AII. In Table 5 , the changes in ASLO titers are compared with the changes in levels of anti-STE, which were determined in the same specimens drawn during the course of the disease from selected cases. All of the 26 cases showing a rise in ASLO titers during the course of the disease showed a rise in levels of anti-STE-AI and/or All; of these 26 cases, 15 showed a simultaneous rise in levels of anti-STE-AI and -All, 7 showed a rise only in anti-STE-AI, and 4 showed a rise only in anti-STEAll. Of eight cases showing no change in ASLO titer, seven showed no marked change in the level of anti-STE-AI and -All and one showed a marked rise in anti-STE-All levels.
Anti-STE-B was found in five cases, one of which showed the presence of only anti-STE-B. The presence of anti-STE-C was shown in 23 cases, all ofwhich showed signs of anti-STE-AL. Figure 2 shows some examples of gel plates that showed marked rises in anti-STE-AI, -All, -C, and -B, along with densitomer tracings (except for Fig. 2C) ; details ofthe data are given in Table 3 .
DISCUSSION
This study demonstrates the distribution of anti-STE-Al, -All, -B, and -C in sera from patients with scarlet fever. Data on the distribution of anti-STE-AI and -AII in positive cases did not differ much from the data reported by Stock and Lynn (4). For comparing the results of ASLO titration and anti-STE determination, the data for the two methods should be interpreted as follows. When (i) the cases showing ASLO titers of 12 or less were defined as ASLO negative and the cases showing ASLO titers of more than 12 were defined as ASLO positive, and (ii) the cases showing no sign of anti-STE-AI and -All were defined as anti-STE negative and the cases showing signs of anti-STE-AI and/or -All were defined as anti-STE positive, marked correlation was observed between the two methods. With these definitions only three cases showed a discrepancy. All of the cases showing a rise in ASLO titers showed a rise in levels ofanti-STE. These facts suggest that the immunological character of STE resembles that of streptolysin ascribed to the difference in enzyme used, because Stock and Lynn (4) used strain H36B (group B, type lb), the same strain we used, for the production of enzyme. As reported in the preceding paper (2), STE-B takes a long time to form the specific reaction complex with homologous antibody, so it is difficult to distinguish the specific immunological reaction product from the nonspecific reaction product. At any rate, the detection of anti-STE-B in human serum is a very interesting problem, because many of the strains of group B streptococci so far as tested produce potent STE. Recently infection by group B streptococcus has been considered as a cause of neonatal infection (1) . This study reveals that about half of the tested cases gave signs of anti-STE-C, and some cases showed a marked increase in antibody to this enzyme during the course of the disease. In the preceding paper (2) we showed that STE-C is immunologically specific, but that STE produced by strain 10706 (group C) is immunologically identical with STE-AI. The problem of classification of STE produced by group C streptococci awaits further study. In this report we did not deal with the problem of STE produced by group G streptococci because we could not find a suitable strain for preparing STE.
Given well-controlled conditions and a suitable standard serum, reproducible results and practical application of the RCE test method should be possible. Moreover, this method is simple and needs a very small blood sample.
